Cannabis: In Focus
Continue Reading Cannabis Legal Report—Week of January 23, 2023
A December 2022 survey from Data for Progress reports that American voters, regardless of political affiliation, support federal cannabis legalization. Specifically, 75% of Democrats, 67% of independents, and 52% of Republicans agreed that cannabis should be legalized at the federal level.
Data for Progress also asked about two equity policies enacted as part of New
As 2022 drew to a close, the Wall Street Journal reported that the FDA is finally considering releasing potential guidance regarding cannabidiol (“CBD”) in the coming year. While the exact timeline and scope of the FDA’s potential action is unclear, the Journal asserts that the agency will decide “within months” regarding the appropriate regulation of CBD and whether that regulation would require Congressional action or new agency rulemaking. Concurrently, the FDA continues to explore potential CBD safety risks.
The agency has generally pursued limited enforcement activity to-date regarding CBD, with a focus on products in foods and beverages that make unsubstantiated health claims, such as claims that CBD could treat or prevent cancer or Covid-19. Stopping short of taking aggressive action, the FDA has only issued warning letters on CBD, despite the widespread availability of largely-unregulated food and beverage products containing the hemp-derived cannabinoid.
Continue Reading Will The New Year Finally Bring FDA Guidance on CBD?
Cannabis: In Focus
Continue Reading Cannabis Legal Report – Week of December 5, 2022
On November 16, 2022, the Food and Drug Administration (FDA) issued five new warning letters to various companies making edible products containing cannabidiol (CBD) and/or Delta-8-tetrahydrocannabinol (THC). The companies were directed by the FDA to respond within 15 days to defend how their products do not violate the Food, Drug, and Cosmetic Act (FDCA) and how they plan to bring their products into compliance with the FDCA. Failure to address the issue to the agency’s satisfaction could plausibly result in enforcement actions, including seizure and/or an injunction.
The FDA’s most recent set of warning letters builds upon warning letters sent earlier this year targeting CBD and Delta-8 THC products. Previously, FDA has largely focused on CBD products that made health claims. These new warning letters are not, however, limited to those prior concerns. The FDA now appears to be particularly concerned about CBD and Delta-8 THC products that appeal to children.
Continue Reading FDA Issues New Warning Letters to Companies Making CBD and Delta-8 THC Edibles
Cannabis: In Focus
Continue Reading Cannabis Legal Report – Week of November 14, 2022
Cannabis: In Focus
Continue Reading Cannabis Legal Report – Week of October 31, 2022
Cannabis: In Focus
Continue Reading Cannabis Legal Report – Week of October 3, 2022
A California state appeals court affirmed a bong maker’s win in a suit alleging it violated California’s Proposition 65 (Prop. 65) by failing to warn consumers that its products expose them to marijuana smoke that could cause cancer or reproductive harm.
Prop. 65 is a California initiative approved by voters in 1986 and enacted into law as the Safe Drinking Water and Toxic Enforcement Act that same year. The law prohibits knowingly and intentionally causing exposure to substances, including cannabis smoke and delta-9-tetrahydrocannabinol (THC), that are known to the state to cause cancer or reproductive harm, without first providing a clear and reasonable warning. California maintains a list of substances that trigger Prop. 65 warnings. To comply with Prop. 65, businesses must provide consumers with a compliant warning, unless they can ensure that their product does not expose consumers to a listed substance at levels that may cause cancer or reproductive harm.
Plaintiff-appellant Environmental Health Advocates, Inc. (EHA) filed a private enforcement action against Sream, Inc. (Sream) on November 12, 2020, alleging Sream violated Prop. 65 when Sream failed to provide a warning that their water pipe products—more commonly known as bongs—exposed consumers to marijuana smoke. EHA’s enforcement action sought “injunctive relief against Sream, from manufacturing, importing, selling, and/or distributing the products without a clear and reasonable warning.”
Continue Reading California State Appeals Court Affirms Bong Maker’s Win in Prop. 65 Suit
Continue Reading Cannabis Legal Report – Week of September 5, 2022